Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer Nakhjavani, Maryam and Shigdar, Sarah 2022, Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer, Pharmacological Research, vol. 175, pp. 1-11, doi: 10.1016/j.phrs.2021.106019. Attached Files Name Description MIMEType Size Downloads Title Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer Author(s) Nakhjavani, Maryam Shigdar, Sarah Journal name Pharmacological Research Volume number 175 Article ID 106019 Start page 1 End page 11 Total pages 11 Publisher Elsevier Place of publication Amsterdam, The Netherlands Publication date 2022 ISSN 1043-6618 1096-1186 Keyword(s) Aptamer Immunotherapy Monoclonal antibody PD-1 PD-L1 Triple-negative breast cancer Language eng DOI 10.1016/j.phrs.2021.106019 Field of Research 1115 Pharmacology and Pharmaceutical Sciences HERDC Research category C1 Refereed article in a scholarly journal Persistent URL http://hdl.handle.net/10536/DRO/DU:30160280 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version Go to link with your DU access privileges   Connect to Elements publication management system Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Fri, 31 Dec 2021, 13:30:18 EST Fri, 31 Dec 2021, 14:48:42 EST Fri, 07 Jan 2022, 12:37:12 EST Tue, 25 Jan 2022, 15:17:17 EST Sat, 12 Feb 2022, 01:45:19 EST Wed, 30 Mar 2022, 15:13:57 EST Wed, 30 Mar 2022, 15:26:42 EST Wed, 30 Mar 2022, 15:32:30 EST Filtered Full Citation counts:   Cited 0 times in TR Web of Science Cited 2 times in Scopus Search Google Scholar Access Statistics: 12 Abstract Views, 1 File Downloads  -  Detailed Statistics Created: Fri, 07 Jan 2022, 12:37:12 EST